Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.

Milanetti F, Germano V, Nisini R, Donatelli I, Di Martino A, Facchini M, Ferlito C, Cappella A, Crialesi D, Caporuscio S, Biselli R, Rossi F, Salemi S, D'Amelio R.

Clin Exp Immunol. 2014 Jul;177(1):287-94. doi: 10.1111/cei.12292.

2.

Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.

Zuccotti GV, Pariani E, Scaramuzza A, Santoro L, Giani E, Macedoni M, Gazzarri A, Anselmi G, Amendola A, Zanetti A.

Diabet Med. 2011 Dec;28(12):1530-6. doi: 10.1111/j.1464-5491.2011.03449.x.

PMID:
21916971
3.

A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli C, Groth N, Levin Y, Del Giudice G.

Hum Vaccin Immunother. 2014;10(6):1701-10. doi: 10.4161/hv.28618. Epub 2014 Apr 14.

PMID:
24732325
4.

Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.

Viganò A, Giacomet V, Pariani E, Giani E, Manfredini V, Bedogni G, Erba P, Amendola A, Zanetti A, Zuccotti G.

Clin Vaccine Immunol. 2011 Sep;18(9):1503-9. doi: 10.1128/CVI.05200-11. Epub 2011 Jul 27.

5.

A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.

Herbinger KH, von Sonnenburg F, Nothdurft HD, Perona P, Borkowski A, Fragapane E, Nicolay U, Clemens R.

Hum Vaccin Immunother. 2014;10(1):92-9. doi: 10.4161/hv.26495. Epub 2013 Sep 20.

6.

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.

Banzhoff A, Haertel S, Praus M.

Hum Vaccin. 2011 May;7(5):539-48. Epub 2011 May 1.

PMID:
21422814
7.

Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.

Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.

Clin Vaccine Immunol. 2011 Aug;18(8):1358-64. doi: 10.1128/CVI.05111-11. Epub 2011 Jun 29.

8.

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.

Knuf M, Leroux-Roels G, Rümke HC, Abarca K, Rivera L, Lattanzi M, Pedotti P, Arora A, Kieninger-Baum D, Della Cioppa G.

Pediatr Infect Dis J. 2014 Dec;33(12):e320-9. doi: 10.1097/INF.0000000000000462.

PMID:
24978857
9.

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.

Solares AR, Aragon CG, Pivaral RU, Prado-Cohrs D, Sales-Carmona V, Pellegrini M, Groth N.

J Infect Dev Ctries. 2014 Sep 12;8(9):1160-8. doi: 10.3855/jidc.4594.

10.

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.

Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.

Vaccine. 2011 Nov 15;29(49):9209-13. doi: 10.1016/j.vaccine.2011.09.103. Epub 2011 Oct 3.

PMID:
21974995
11.

Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.

Dell'Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S.

Vaccine. 2012 Jan 20;30(5):936-40. doi: 10.1016/j.vaccine.2011.11.083. Epub 2011 Dec 3.

PMID:
22138210
12.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
13.

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.

Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6.

PMID:
22801094
14.
16.

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients.

Esposito S, Meregalli E, Daleno C, Ghio L, Tagliabue C, Valzano A, Serra D, Galeone C, Edefonti A, Principi N.

Nephrol Dial Transplant. 2011 Jun;26(6):2018-24. doi: 10.1093/ndt/gfq657. Epub 2010 Oct 25.

17.

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.

Vaccine. 2010 Oct 21;28(45):7331-6. doi: 10.1016/j.vaccine.2010.08.075. Epub 2010 Sep 15.

PMID:
20813217
18.

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A.

Pediatr Infect Dis J. 2009 Jul;28(7):563-71. doi: 10.1097/INF.0b013e31819d6394.

PMID:
19561422
19.

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.

Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.

Pediatrics. 2011 May;127(5):e1161-8. doi: 10.1542/peds.2010-1920. Epub 2011 Apr 4.

PMID:
21464195
20.

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N.

Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545.

PMID:
22418661
Items per page

Supplemental Content

Write to the Help Desk